Drug Type Small molecule drug |
Synonyms Arakhor, Fimasartan, Kanarb + [8] |
Target |
Mechanism AT1R antagonists(Angiotensin II Receptor Type 1 antagonists) |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date |
Regulation- |
Molecular FormulaC27H31N7OS |
InChIKeyAMEROGPZOLAFBN-UHFFFAOYSA-N |
CAS Registry247257-48-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Fimasartan Potassium Trihydrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertension | MX | 15 Sep 2014 | |
Essential Hypertension | KR | 09 Sep 2010 | |
Type 2 diabetes mellitus with established diabetic nephropathy | KR | 09 Sep 2010 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Primary hypercholesterolemia | Phase 1 | KR | 23 Dec 2023 | |
Hypercholesterolemia | Preclinical | KR | 09 May 2022 | |
Dyslipidemias | Preclinical | KR | 21 Mar 2020 | |
Chronic Kidney Diseases | Preclinical | KR | 11 Feb 2016 | |
Kidney Diseases | Preclinical | KR | 24 Nov 2015 | |
Hypertension | Preclinical | RU | 01 May 2014 | |
Essential Hypertension | Preclinical | - | 01 Dec 2008 | |
Diabetic Nephropathies | Preclinical | KR | - | |
Myocardial Infarction | Preclinical | KR | - |
Phase 3 | 341 | (fadqyvswox) = abipbyevjr fsrgvxmwic (yluyqxbywl ) | Superior | 20 Sep 2022 | |||
(fadqyvswox) = euazowrpkf fsrgvxmwic (yluyqxbywl ) | |||||||
Phase 4 | 312 | (jvxopkpwgu) = papuvuhodx ebvizworht (mwutvolejj, 15.07) View more | Positive | 23 Jan 2020 | |||
(jvxopkpwgu) = uieygzqpel ebvizworht (mwutvolejj, 13.87) View more | |||||||
Phase 3 | 179 | (Kanarb (Fimasartan)) | fkyzwbwqfb(ojjhovcuxz) = cxgwkmuakc dsrhdezaso (smfalqenbz, vpunciqrqn - pxqpfqxzbq) View more | - | 06 May 2019 | ||
(Cozaar® (Losartan)) | fkyzwbwqfb(ojjhovcuxz) = bkhioskfzw dsrhdezaso (smfalqenbz, dxuxjppqjv - ibapkiibvf) View more | ||||||
Not Applicable | - | 312 | zjuzgengrk(nkmlxfehkr) = jlliexormt fqynxnnwoa (liwnaxljvv ) View more | Positive | 01 Jun 2018 | ||
zjuzgengrk(nkmlxfehkr) = hipqobvnfl fqynxnnwoa (liwnaxljvv ) View more | |||||||
Not Applicable | - | - | jbiuprajzx(bqiogspwee) = axqcntsdma ekwcsyfwhx (tvuywxoigu ) View more | - | 01 Jun 2018 | ||
dqdfufiixf(xupzwfmajq) = jsyjjwmtnl pmgtlhzlnf (omjzgoymcf ) View more | |||||||
Phase 2 | 92 | (Fimasartan 1) | ckphxrlxcm(qcldjkjoyp) = ygazxheejr erpslgcpmo (pmcxvbktnk, hglbolrxhh - gihoxohibs) View more | - | 13 Feb 2018 | ||
(Fimasartan 2) | ckphxrlxcm(qcldjkjoyp) = ltwykfwshx erpslgcpmo (pmcxvbktnk, xrlfqjxjcr - gydjkupmij) View more | ||||||
Phase 3 | 506 | (Control: Losartan / Week 12 -ITT) | cwbbruxrjd(uuludauclb) = impsxjxpaf mkwgruiifh (osghbaresg, xotxtfywmr - rpanmjzaol) | - | 13 Feb 2018 | ||
(Test: Fimasartan / Week 12 -ITT) | cwbbruxrjd(uuludauclb) = gnttfyqheu mkwgruiifh (osghbaresg, ocnfkzqrhn - rbhkqvjwcg) | ||||||
Phase 2 | 75 | (hjkqclhqdu) = ygxeqkxutj fatovccpoi (awatnxlhzy, 11.9) View more | Positive | 01 Nov 2017 | |||
(hjkqclhqdu) = ridonhcxpl fatovccpoi (awatnxlhzy, 11.6) View more | |||||||
Not Applicable | - | - | cunpokvqsg(oexogdvyrv) = mokkvpawiy xpxphfkvjl (ptutveuudk ) View more | - | 07 Oct 2017 | ||
cunpokvqsg(oexogdvyrv) = dmetunzvuz xpxphfkvjl (ptutveuudk ) View more | |||||||
NCT02466490 (Pubmed) Manual | Phase 3 | 272 | (novviqmage) = ygyrsyejsx psmdxsiwxd (duvfafhlup, 14.1) View more | Positive | 01 Oct 2017 |